## **Core Concept**
The question revolves around the management of hypertension in a diabetic patient with proteinuria. The key concept here is to identify an antihypertensive drug that not only lowers blood pressure but also provides renal protection, particularly in the context of diabetic nephropathy.

## **Why the Correct Answer is Right**
The correct answer, **C. ACE inhibitors (or ARBs)** , is appropriate for several reasons:
- **ACE inhibitors** (Angiotensin-Converting Enzyme inhibitors) and **ARBs** (Angiotensin Receptor Blockers) are known to have renoprotective effects. They reduce intraglomerular pressure and decrease proteinuria, which is beneficial in diabetic nephropathy.
- They work by inhibiting the renin-angiotensin-aldosterone system (RAAS), which plays a critical role in regulating blood pressure and electrolyte balance.
- **Clinical trials** have shown that ACE inhibitors and ARBs slow the progression of diabetic nephropathy and reduce the risk of cardiovascular events.

## **Why Each Wrong Option is Incorrect**
- **Option A:** Beta-blockers are useful in managing hypertension and have a role in patients with heart failure or post-myocardial infarction. However, they do not have specific renoprotective effects like ACE inhibitors or ARBs in diabetic patients with proteinuria.
- **Option B:** Calcium channel blockers are effective in lowering blood pressure and are often used in combination with other agents. While they can provide some renal protection through blood pressure reduction, they do not have the specific renoprotective effects of ACE inhibitors or ARBs.
- **Option D:** Diuretics, particularly thiazide diuretics, are commonly used in hypertension management. However, they do not offer the same level of renoprotection as ACE inhibitors or ARBs in diabetic patients with proteinuria.

## **Clinical Pearl / High-Yield Fact**
A crucial point to remember is that in diabetic patients with proteinuria, **ACE inhibitors or ARBs** are considered first-line antihypertensive agents due to their renoprotective effects. However, it's essential to monitor potassium levels and renal function (e.g., serum creatinine) when initiating these therapies, as they can cause hyperkalemia and worsen renal function in some patients.

## **Correct Answer:** . ACE inhibitors (or ARBs)